OPT-302 is an investigational medication being studied for its potential to treat neovascular age-related macular degeneration (nAMD). It is administered through an injection into the eye, known as an intravitreal injection. The purpose of this medication in the trial is to evaluate its effectiveness and safety when used in combination with another medication, aflibercept, to improve vision in patients with nAMD.

Aflibercept is a medication already used to treat neovascular age-related macular degeneration (nAMD). It works by blocking the growth of abnormal blood vessels in the eye, which can help prevent vision loss. In this trial, aflibercept is used both alone and in combination with OPT-302 to compare the outcomes and determine if the combination provides better results for patients with nAMD.

Neovascular Age-related Macular Degeneration (wet AMD) – This is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It occurs when abnormal blood vessels grow under the retina and macula, leading to leakage of blood and fluid. This leakage can cause the macula to lift from its normal position, damaging the retina and leading to vision loss. The disease progresses as these abnormal blood vessels continue to grow and leak, further impairing vision. Over time, this can result in significant vision impairment if not managed. Wet AMD is one of the leading causes of vision loss in older adults.